Home > Insider Trading > Filing (0000899243-21-002048)

Filing Details

Accession Number:: 0000899243-21-002048
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-14 17:30:41
Reporting Period:: 2021-01-12

Accepted Time:: 2021-01-14 17:30:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1789972	Cullinan Management Inc.	CGEM	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1575745	Morana Jovan-Embiricos	C/O Cullinan Management, Inc. One Main Street, Suite 520 Cambridge MA 02142	Yes	No	Yes	No
1600769	Ltd Holdings Globeways	C/O Lj Partnership, 8, Rue Saint-Leger, Geneva V8 CH-1205	No	No	Yes	No
1767396	Ltd Mg F2	C/O Lj Partnership, 8, Rue Saint-Leger Geneva V8 CH-1205	No	No	Yes	No
1767397	F2 - Tpo Investments Llc	C/O Singer, Mckeon Inc. 8 West 38Th Street, Suite 1001 New York NY 10018	No	No	Yes	No
1838330	F2 Bio Td, Llc	C/O Singer, Mckeon Inc. 8 West 38Th Street, Suite 1001 New York NY 10018	No	No	Yes	No
1838409	Scs Vision F2	C/O Atalux 74 Grand-Rue Luxembourg V8 L-1660	No	No	Yes	No
1838426	F2 Mc, Llc	C/O Singer, Mckeon Inc. 8 West 38Th Street, Suite 1001 New York NY 10018	No	No	Yes	No
1838573	Ltd 2017 I Bioscience F2	C/O Lj Partnership, 8, Rue Saint-Leger, Geneva V8 CH-1205	No	No	Yes	No
1840637	F2 Gc, Llc	C/O Singer, Mckeon Inc. 8 West 38Th Street, Suite 1001 New York NY 10018	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-01-12	1,136,525	$0.00	1,136,525	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-01-12	2,912,345	$0.00	2,912,345	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-01-12	639,295	$0.00	639,295	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-01-12	455,338	$0.00	455,338	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-01-12	182,135	$0.00	182,135	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-01-12	71,599	$0.00	526,937	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-01-12	143,198	$0.00	325,333	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-01-12	71,599	$0.00	71,599	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-01-12	214,798	$0.00	214,798	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-01-12	95,238	$21.00	622,175	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2021-01-12	104,762	$21.00	104,762	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series Seed Convertible Preferred Stock	Disposition	2021-01-12	8,000,000	$0.00	1,136,525	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2021-01-12	20,500,000	$0.00	2,912,345	$0.00
Common Stock	Series A Convertible Preferred Stock	Disposition	2021-01-12	4,500,000	$0.00	639,295	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2021-01-12	3,205,128	$0.00	455,338	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2021-01-12	1,282,051	$0.00	182,135	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2021-01-12	503,988	$0.00	71,599	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2021-01-12	1,007,977	$0.00	143,198	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2021-01-12	503,988	$0.00	71,599	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2021-01-12	1,511,966	$0.00	214,798	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	112,507	Direct

Footnotes

Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the "Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021. The Preferred Stock had no expiration date.
These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.